Successful Treatment of Refractory Guillain-Barre Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia

被引：11

作者：

Tzachanis, Dimitrios ^{[1
]}

Hamdan, Ayad ^{[2
]}

Uhlmann, Erik J. ^{[2
]}

Joyce, Robin M. ^{[2
]}

机构：

[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

来源：

ACTA HAEMATOLOGICA | 2014年 / 132卷 / 02期

关键词：

Alemtuzumab; Antiganglioside GQ1b antibody; Bendamustine; Bickerstaff brainstem encephalitis; Chronic lymphocytic leukemia; Guillain-Barre syndrome; Miller Fisher syndrome; Rituximab; INFLAMMATORY DEMYELINATING POLYNEUROPATHY; BRAIN-STEM ENCEPHALITIS; FISHER-SYNDROME; RITUXIMAB THERAPY; ANTIBODY SYNDROME; COMPLICATIONS; NEUROPATHIES; NEUTROPENIA; CANCER; CLL;

D O I：

10.1159/000358292

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This is the case of a 79-year-old man with chronic lymphocytic leukemia who presented with Guillain-Barre syndrome with features overlapping with the Miller Fisher syndrome and Bickerstaff brainstem encephalitis and positive antiganglioside GQ1b antibody about 6 months after treatment with bendamustine and rituximab. His clinical and neurologic condition continued to deteriorate despite sequential treatment with corticosteroids, intravenous immunoglobulin and plasmapheresis, but in the end, he had a complete and durable response to treatment with alemtuzumab. (C) 2014 S. Karger AG, Basel

引用

页码：240 / 243

页数：4

共 42 条

[1] Guillain-Barre syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: A case report and review of the literature [J].